Comparison of Two Marketed Silicone Hydrogel Lenses
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02495948 |
|
Recruitment Status :
Completed
First Posted : July 13, 2015
Results First Posted : October 19, 2016
Last Update Posted : December 28, 2016
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Refractive Error | Device: Lotrafilcon B contact lenses Device: Samfilcon A contact lenses Device: Hydrogen peroxide solution Device: Saline solution | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 168 participants |
| Allocation: | Randomized |
| Intervention Model: | Crossover Assignment |
| Masking: | Single (Participant) |
| Official Title: | One Month Clinical Comparison of Lotrafilcon B and Samfilcon A |
| Study Start Date : | July 2015 |
| Actual Primary Completion Date : | October 2015 |
| Actual Study Completion Date : | October 2015 |
| Arm | Intervention/treatment |
|---|---|
|
AOA then ULTRA
Lotrafilcon B contact lenses worn first, followed by samfilcon A contact lenses. Each product worn bilaterally (in both eyes) for a minimum of 5 days/week, 8 hours/day for 30 days in a daily wear modality.
|
Device: Lotrafilcon B contact lenses
Other Name: AIR OPTIX® AQUA Device: Samfilcon A contact lenses Other Name: Bausch + Lomb ULTRA Device: Hydrogen peroxide solution Used as a cleaning, disinfection, and storage solution for silicone hydrogel and soft contact lenses
Other Name: CLEAR CARE® Device: Saline solution Used for rinsing contact lenses, as needed
Other Name: SENSITIVE EYES® PLUS |
|
ULTRA then AOA
Samfilcon A contact lenses worn first, followed by lotrafilcon B contact lenses. Each product worn bilaterally for a minimum of 5 days/week, 8 hours/day for 30 days in a daily wear modality.
|
Device: Lotrafilcon B contact lenses
Other Name: AIR OPTIX® AQUA Device: Samfilcon A contact lenses Other Name: Bausch + Lomb ULTRA Device: Hydrogen peroxide solution Used as a cleaning, disinfection, and storage solution for silicone hydrogel and soft contact lenses
Other Name: CLEAR CARE® Device: Saline solution Used for rinsing contact lenses, as needed
Other Name: SENSITIVE EYES® PLUS |
- Mean Ex-vivo Cholesterol Deposits After 30 Days of Wear [ Time Frame: Day 30, each product ]The contact lens (right eye) was removed and stored dry and frozen until analysis. Total cholesterol deposits (cholesterol and cholesterol esters) were extracted from the lens and measured in micrograms. Lower deposits indicate increased lens performance. Study originally intended to analyze 36 lenses per arm, but actual number of lenses analyzed was less due to measurement error.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Sign informed consent document;
- Vision correctable to 20/40 Snellen (feet) or better in each eye at distance with both study contact lenses;
- Willing to wear study lenses on a daily basis (minimum 5 days/week, 8 hours/day) and attend all study visits;
- Successful wear of single-vision spherical, 2-week/ monthly replacement silicone hydrogel contact lenses in both eyes daily wear during the past 2 months for a minimum of 5 days/week, 8 hours/day. (Note: Monovision is included);
- Other protocol-specified inclusion criteria may apply.
Exclusion Criteria:
- Any anterior segment infection, inflammation, disease or abnormality that contraindicates contact lens wear (within 7 days of enrollment, or current);
- History of herpetic keratitis, corneal surgery or irregular cornea;
- Any use of systemic or ocular medications within the past 30 days for which contact lens wear could be contraindicated as determined by the investigator;
- Monocular (only 1 eye with functional vision) or fit with only one lens;
- Current or past AIR OPTIX® AQUA or ULTRA lens wearers;
- Other protocol-specified exclusion criteria may apply.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02495948
| Study Director: | Clinical Trial Manager, Vision Care, GCRA | Alcon, A Novartis Division |
| Responsible Party: | Alcon Research |
| ClinicalTrials.gov Identifier: | NCT02495948 |
| Other Study ID Numbers: |
CLA560-P001 |
| First Posted: | July 13, 2015 Key Record Dates |
| Results First Posted: | October 19, 2016 |
| Last Update Posted: | December 28, 2016 |
| Last Verified: | November 2016 |
|
Refractive Errors Eye Diseases Hydrogen Peroxide |
Pharmaceutical Solutions Anti-Infective Agents, Local Anti-Infective Agents |

